Robert A. Kyle, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Robert A. Kyle, MD

Robert A. Kyle, MD

Healthcare Professional
Professor
Department of Hematology
Mayo Clinic
200 First St. SW
Rochester, Minnesota, United States

Robert A. Kyle is a Hematology specialist and Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota. Dr. Kyle completed his graduation from University of North Dakota and MD from Northwestern University Feinberg School of Medicine, followed by MS from University of Minnesota, Twin Cities. Dr. Kyle completed Residency from Mayo Clinic Minnesota and Research Fellowship in Hematology from Tufts University School of Medicine.

Dr. Robert Kyle has catalogued patient histories, archived blood samples and observed a vast number of people with plasma cell proliferative disorders from more than 60 years. His methodical examination of the data allowed him to classify these disorders into various groups like benign monoclonal gammopathy of undetermined significance, intermediate smoldering multiple myeloma and severe multiple myeloma.

Dr. Kyle also launched the dysproteinemia group at Mayo Clinic, which is now the strongest and largest such team in the world. In 1974, the National Institutes of Health awarded Dr. Kyle and his colleagues a program project grant to study monoclonal gammopathies which consisted of several closely related projects conducted by collaborating investigators.

 

Representative Publications:

Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis 

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma 

Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015

Comparative analysis of staging systems in AL amyloidosis

view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close